搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 24 小时
时间不限
过去 1 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
12 小时
Investors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five years
Take a more thorough look at UroGen Pharma's financial health with this free report on its balance sheet.
19 小时
Astellas Pharma Inc.: Astellas' VYLOY (zolbetuximab-clzb) Approved by U.S. FDA for ...
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO, Oct. 18 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Reaches tentative union deal
Boat rider arrested in FL
Postpones US tour
Hurricane Oscar forms
Philip Zimbardo dies at 91
Frozen waffles recalled
NC breaks turnout record
Nationwide blackout in Cuba
OK classroom Bible suit
Fire prompts evacuations
2024 induction ceremony
Three Americans detained
At decade-high level
Challenges military listing
School shooting report
Ex-MN congressman dies
Probes near miss in Austin
Calif. oil refinery closure
US deficit reaches $1.8T
Netanyahu's home targeted
PG&E shuts off power
Republicans appeal ruling
Judge unseals new evidence
Opioid suits settlement deal
La Nina could arrive soon
To furlough 700 workers
Antitrust ruling delayed
NK sending troops to RU?
Bladder cancer drug pulled
G7 ministers back Ukraine
$4M LAPD fentanyl seizure
Emergency abortion ruling
反馈